Search





Search





Markets
/
Stocks
/
tgtx
/

TG Therapeutics Inc

TGTX

Add to Watchlist

54.860USD

-0.890-1.60%

Close 07-28 16:00（ET）Quotes delayed by 15 min

8.40BMarket Cap

17.14P/E TTM

TG Therapeutics Inc

54.860

-0.890-1.60%

Overview

Financials

Discussions

Analysis

Company

View Detailed Chart

TradingKey Chart

Intraday

30m

Today

-1.60%

5 Days

+1.67%

1 Month

-1.74%

6 Months

+78.12%

Year to Date

+84.03%

1 Year

+48.67%

Key Figures

56.000Open

56.281High

2.29MVolume

17.14P/E TTM

17.24P/E Dynamic

--Dividend TTM

1.50%Turnover Ratio

55.750Prev. Close

54.610Low

103.89MTurnover

359.18P/E Static

14.40P/B

0.00%Div Yield TTM

42.27%ROA

46.48052wk High

1.29Volume Ratio

23.38MNet Profit

153.09MShares

3.2010EPS TTM

1.68Beta

112.60%ROE

25.28052wk Low

3.00%Amplitude

83.65%Gross Margin

8.40BMarket Cap

0.02Reward/Risk

2.71%Risk Rate

TradingKey Stock Score of TG Therapeutics Inc

Currency: USD Updated: 2026-07-27

Key Insights

TG Therapeutics Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 40 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 62.67.In the medium term, the stock price is expected to trend up.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

TG Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

40 / 155

Overall Ranking

100 / 4282

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Positive

TG Therapeutics Inc Highlights

StrengthsRisks

TG Therapeutics, Inc. is a fully integrated, commercial stage, biopharmaceutical company. The Company is focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. Its clinical drug candidates are Ublituximab IV (anti-CD20 mAb), Ublituximab Subcutaneous (anti-CD20 mAb), Azer-cel, TG-1701 (BTK inhibitor), and TG-1801 (anti-CD47/CD19 bispecific mAb). BRIUMVI is an anti-CD20 monoclonal antibody for the treatment of RMS, which includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. TG-1701 is a novel, orally available and covalently bound Bruton’s tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening. TG-1801 is a bispecific CD47 and CD19 antibody. It also evaluates complementary products, technologies and companies for in-licensing, partnership, acquisition, and/or investment opportunities.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 163.75% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 616.29M.

Fairly Valued

The company’s latest PE is 17.42, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 122.50M shares, increasing 3.47% quarter-over-quarter.

Held by Ray Dalio

Star Investor Ray Dalio holds 264.03K shares of this stock.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

62.667

Target Price

+11.82%

Upside Space

TG Therapeutics Inc News

More news coming soon, stay tuned...

Earnings Forecast

Analyst Rating

Based on 8 analysts

Buy

Current Rating

67.833

Target Price

+21.04%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

160

Total

Median

Average

Company name

Ratings

Analysts

TG Therapeutics Inc

TGTX

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

Pfizer Inc

PFE

AbbVie Inc

ABBV

...

Indicators

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.053

Neutral

RSI(14)

54.868

Neutral

STOCH(KDJ)(9,3,3)

62.340

Neutral

ATR(14)

2.323

High Vlolatility

CCI(14)

-7.418

Neutral

Williams %R

55.237

Sell

TRIX(12,20)

0.344

Sell

StochRSI(14)

54.135

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

54.968

Sell

MA10

54.896

Sell

MA20

55.378

Sell

MA50

49.112

Buy

MA100

41.614

Buy

MA200

36.396

Buy

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

TG Therapeutics Inc Info

Ticker SymbolTGTX

CompanyTG Therapeutics Inc

CEOWeiss (Michael S)

Websitehttps://www.tgtherapeutics.com/

Shareholders

Shareholders

Proportion

BlackRock Institutional Trust Company, N.A.

12.51%

Weiss (Michael S)

6.39%

State Street Investment Management (US)

5.54%

Vanguard Portfolio Management, LLC

5.40%

Vanguard Capital Management, LLC

4.31%

Other

65.85%

Popular Instruments

FAQs

What is the current price of TG Therapeutics Inc (TGTX)?



The current price of TG Therapeutics Inc (TGTX) is 55.76.

What is the symbol of TG Therapeutics Inc?



The ticker symbol of TG Therapeutics Inc is TGTX.

What is the 52-week high of TG Therapeutics Inc?



The 52-week high of TG Therapeutics Inc is 46.48.

What is the 52-week low of TG Therapeutics Inc?



The 52-week low of TG Therapeutics Inc is 25.28.

What is the market capitalization of TG Therapeutics Inc?



The market capitalization of TG Therapeutics Inc is 8.54B.

Is TG Therapeutics Inc (TGTX) currently rated as Buy, Hold, or Sell?



According to analysts, TG Therapeutics Inc (TGTX) has an overall rating of Buy, with a price target of 62.67.

What is the Earnings Per Share (EPS TTM) of TG Therapeutics Inc (TGTX)?



The Earnings Per Share (EPS TTM) of TG Therapeutics Inc (TGTX) is 3.10.